Evidence map›Paper›PMID 33653293›Full record

ArticleBMC gastroenterology2021

Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study.

Yariv Gerber, Lisa B VanWagner, Kristine Yaffe, James G Terry, Jamal S Rana, Jared P Reis, Stephen Sidney

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. The Mind From Within: Visceral Roots of Human Cognition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Metabolic Parkinson's disease.Frontiers in aging neuroscience · 2025
    Review
  9. Review
  10. Liver integrity and the risk of Alzheimer's disease and related dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Yariv GerberDepartment of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. yarivg@tauex.tau.ac.il.
Lisa B VanWagnerNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Kristine YaffeDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
James G TerryVanderbilt University Medical Center, Nashville, TN, USA.
Jamal S RanaKaiser Permanente Northern California, Oakland, CA, USA.
Jared P ReisNational Heart Lung and Blood Institute, Bethesda, MD, USA.
Stephen SidneyKaiser Permanente Northern California, Oakland, CA, USA.
University of California, San Francisco · USBerkeley Public Health Division · USKaiser Permanente · USNational Heart Lung and Blood Institute · USNorthwestern University · USVanderbilt University Medical Center · US

Funding

Lifecourse CVD Risk and Midlife Cognitive Trajectories and Brain Aging: Implications for Alzheimer's and Dementia PreventionR01AG063887 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YAFFE, KRISTINE · 2019 to 2022
$3.0M
NIA NIH HHS R01 AG063887
6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is associated with cardiovascular disease (CVD) risk factors that have been linked to cognitive decline. Whether NAFLD is associated with cognitive performance in midlife remains uncertain.

methodsCoronary Artery Risk Development in Young Adults study participants with CT examination and cognitive assessment at Y25 (2010-2011; n = 2809) were included. Cognitive function was reassessed at Y30. NAFLD was defined according to liver attenuation and treated both continuously and categorically (using ≤ 40 and ≤ 51 Hounsfield units to define severity) after exclusion for other causes of liver fat. Cognitive tests including the Digit Symbol Substitution (processing speed), Rey Auditory Verbal Learning (verbal memory), and Stroop (executive function) were analyzed with standardized z-scores. Linear models were constructed to (a) examine the cross-sectional associations of NAFLD with cognitive scores and (b) evaluate its predictive role in 5-year change in cognitive performance.

resultsParticipants' mean age (Y25) was 50.1 (SD 3.6) years (57% female; 48% black), with 392 (14%) having mild NAFLD and 281 (10%) having severe NAFLD. NAFLD was positively associated with CVD risk factors and inversely associated with cognitive scores. However, after adjustment for CVD risk factors, no associations were shown between NAFLD and cognitive scores (all βs ≈ 0). Similarly, no associations were observed with 5-year cognitive decline. CVD history, hypertension, smoking, diabetes and hypertriglyceridemia showed stronger associations with baseline cognitive scores and were predictive of subsequent cognitive decline (all P ≤ .05).

conclusionAmong middle-aged adults, inverse associations between NAFLD and cognitive scores were attenuated after adjustment for CVD risk factors, with the latter predictive of poorer cognitive performance both at baseline and follow-up.

Indexed as

Non-alcoholic Fatty Liver DiseaseCognitionCross-Sectional StudiesFemaleHumansMaleMemoryMiddle AgedRisk FactorsYoung AdultCardiovascular diseaseCognitive declineCognitive performanceNeurological risk factorsNon-alcoholic fatty liver disease

Identifiers

PMID33653293
PMCPMC7927393
OpenAlexW3134624331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.